NADIM II trial provides support for neoadjuvant chemoimmunotherapy for patients with non-small cell lung cancer
In the initial NADIM trial, neoadjuvant chemoimmunotherapy was shown to be highly effective in patients with resectable stage IIIA non-small […]
Learn more →